Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04462406
Title Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors ECOG-ACRIN Cancer Research Group
Indications

melanoma

Therapies

Pembrolizumab

Nivolumab + Pembrolizumab

Ipilimumab + Nivolumab

Ipilimumab + Pembrolizumab

Nivolumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.